产品
编 号：F200417
分子式：C29H31ClF3N5O3
分子量：590.04
分子式：C29H31ClF3N5O3
分子量：590.04
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1673571-51-1
产品详情
生物活性：
Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH).
体内研究：
Rodatristat ethyl (100 or 200 mg/kg; oral administration; once daily; for 28 days; male Sprague-Dawley rats) treatment decreases erum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduces pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male ratswith monocrotaline (MCT).Animal Model:Male Sprague-Dawley rats (175-200 g)
Dosage:100 mg/kg or 200 mg/kg
Administration:Oral administration; once daily; for 28 days
Result:Decreased serum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduced pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats.
Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH).
体内研究：
Rodatristat ethyl (100 or 200 mg/kg; oral administration; once daily; for 28 days; male Sprague-Dawley rats) treatment decreases erum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduces pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male ratswith monocrotaline (MCT).Animal Model:Male Sprague-Dawley rats (175-200 g)
Dosage:100 mg/kg or 200 mg/kg
Administration:Oral administration; once daily; for 28 days
Result:Decreased serum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduced pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备